Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy
Y Fujita, AM Leen, J Sun, Y Nakazawa… - Journal of …, 2008 - journals.lww.com
Viral infections remain a major cause of morbidity and mortality after hematopoietic stem cell
transplantation (HSCT), and conventional small-molecule therapeutics often have modest
benefit, high cost, and adverse effects. Adoptive transfer of donor-derived virus-specific T
cells has proved feasible and safe after HSCT and to reconstitute immunity against
cytomegalovirus, Epstein-Barr virus, and adenovirus. Current protocols to generate these
cytotoxic T cell lines are lengthy, taking up to 12 weeks. As viral infections often occur< 30 …
transplantation (HSCT), and conventional small-molecule therapeutics often have modest
benefit, high cost, and adverse effects. Adoptive transfer of donor-derived virus-specific T
cells has proved feasible and safe after HSCT and to reconstitute immunity against
cytomegalovirus, Epstein-Barr virus, and adenovirus. Current protocols to generate these
cytotoxic T cell lines are lengthy, taking up to 12 weeks. As viral infections often occur< 30 …